Latest Bioethics Stories
Just in time for Autism Awareness Month! HCI announces the release of Aspertools: The Practical Guide for Understanding and Embracing Asperger’s, Autism Spectrum Disorders, and Neurodiversity
The Study did not achieve its primary efficacy endpoint PETACH TIKVA, Israel, March 30, 2015 /PRNewswire/ -- Can-Fite
PRINCETON, N.J., March 24, 2015 /PRNewswire/ -- Soligenix, Inc.
TOKYO and SAN FRANCISCO, March 24, 2015 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc.
COSTA MESA, Calif., March 20, 2015 /PRNewswire-iReach/ -- WCCT Global, a contract research organization headquartered in Orange County, CA, successfully completed a Phase 2 ophthalmology
NORTHBROOK, Ill. and SAN FRANCISCO, March 16, 2015 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc.
Randomized, Blinded, Placebo-Controlled Phase 2 Study Meets Its Primary Endpoint. SAN FRANCISCO, March 16, 2015 /PRNewswire/ -- Kindred Biosciences, Inc.
Clients and staff at Best Drug Rehabilitation program bring awareness to animals in need by volunteering at local animal shelter while undergoing treatment. Manistee,
A Review of Conditions that Can Be Caused by Bioterrorism BALTIMORE, March 4, 2015 /PRNewswire-USNewswire/ -- In an article published and posted online today, senior scholars at the
The OncoMouse or Harvard Mouse is a type of laboratory mouse that has been genetically modified utilizing modification designed by Philip Leder and Timothy A. Stewart, of Harvard University, to carry a certain gene called an activated oncogene. The activated oncogene considerably increases the mouse’s vulnerability to cancer, therefore making the mouse suitable for cancer research. The rights to the invention were owned by DuPont until recently. The USPTO found that the patent expired in...
- A person in a secondary role, specifically the second most important character (after the protagonist).
More Images (1 images) »